Cytek Biosciences Inc. (NASDAQ:CTKB) is one of the 8 Best Life Sciences Penny Stocks to Buy. As of the April 8 closing, the consensus sentiment around Cytek Biosciences Inc. (NASDAQ:CTKB) remained ...

Good afternoon all, and welcome. My name is Fazi Kash, and I'll be moderating today's session. It is my pleasure to introduce Dr. Jiang, CEO and Chair; and Bill McCombe, CFO; Paul Goodson, Head of IR, ...

Cytek Biosciences has reported relatively small net losses, indicating that its financial position has not deteriorated significantly. In Q2 2025, the company had liquid assets of $262.02 million.

Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024 Expanded to a total installed base of 3,295 Cytek instruments, adding ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company, which makes devices ...

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) has announced the launch of its latest innovation, the Cytek Aurora Evo system, marking a significant leap forward in flow cytometry technology. Building on the ...

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell ...

Cytek Biosciences (NASDAQ:CTKB – Free Report) had its price objective reduced by Morgan Stanley from $9.00 to $7.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an ...

FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ ...